PDF(Sci-hub)
Abstract：
The clinical management of inflammatory pain requires an optimal balance between effective analgesia and associated safety risks. To date, mechanisms associated with inflammatory pain are not completely understood because of their complex nature and the involvement of both peripheral and central mechanisms. This Expert Consensus document is intended to update clinicians about evolving areas of clinical practice and/or available treatment options for the management of patients with inflammatory pain.
An international group of experts in pain management covering the pharmacology, neurology and rheumatology fields carried out an independent qualitative systematic literature search using MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials.
Existing guidelines for pain management provide recommendations that do not satisfactorily address the complex nature of pain. To achieve optimal outcomes, drug choices should be individualized to guarantee the best match between the characteristics of the patient and the properties of the medication. NSAIDs represent an important prescribing choice in the management of inflammatory pain, and the recent results on paracetamol question its appropriate use in clinical practice, raising the need for re-evaluation of the recommendations in the clinical practice guidelines.
Increasing clinicians\' knowledge of the available pharmacologic options to treat different pain mechanisms offers the potential for safe, individualized treatment decisions. We hope that it will help implement the needed changes in the management of inflammatory pain by providing the best strategies and new insights to achieve the ultimate goal of managing the disease and obtaining optimal benefits for patients.
Dompé Farmaceutici SPA and Paolo Procacci Foundation.
An international group of experts in pain management covering the pharmacology, neurology and rheumatology fields carried out an independent qualitative systematic literature search using MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials.
Existing guidelines for pain management provide recommendations that do not satisfactorily address the complex nature of pain. To achieve optimal outcomes, drug choices should be individualized to guarantee the best match between the characteristics of the patient and the properties of the medication. NSAIDs represent an important prescribing choice in the management of inflammatory pain, and the recent results on paracetamol question its appropriate use in clinical practice, raising the need for re-evaluation of the recommendations in the clinical practice guidelines.
Increasing clinicians\' knowledge of the available pharmacologic options to treat different pain mechanisms offers the potential for safe, individualized treatment decisions. We hope that it will help implement the needed changes in the management of inflammatory pain by providing the best strategies and new insights to achieve the ultimate goal of managing the disease and obtaining optimal benefits for patients.
Dompé Farmaceutici SPA and Paolo Procacci Foundation.
摘要：
炎性疼痛的临床管理需要有效镇痛和相关安全风险之间的最佳平衡。迄今为止,与炎性疼痛相关的机制尚未完全了解，因为它们的性质复杂，并且涉及外周和中枢机制。本专家共识文件旨在使临床医生了解临床实践领域的发展和/或治疗炎性疼痛患者的可用治疗方案。
一个涵盖药理学的疼痛管理国际专家组，神经病学和风湿病学领域使用MEDLINE进行了独立的定性系统文献检索，EMBASE和Cochrane中央受控试验登记册。
现有的疼痛管理指南提供的建议不能令人满意地解决疼痛的复杂性。为了获得最佳结果，药物选择应个性化，以确保患者的特征与药物特性之间的最佳匹配。NSAIDs是治疗炎症性疼痛的重要处方选择，扑热息痛的最新结果质疑其在临床实践中的适当使用，提高了对临床实践指南中的建议进行重新评估的必要性。
增加临床医生对治疗不同疼痛机制的可用药理学选择的了解提供了潜在的安全，个性化治疗决策。我们希望它将通过提供最佳策略和新见解来帮助实现炎症性疼痛管理所需的变化，以实现管理疾病并为患者获得最佳利益的最终目标。
DompéFarmaceuticiSPA和PaoloProcacci基金会。
一个涵盖药理学的疼痛管理国际专家组，神经病学和风湿病学领域使用MEDLINE进行了独立的定性系统文献检索，EMBASE和Cochrane中央受控试验登记册。
现有的疼痛管理指南提供的建议不能令人满意地解决疼痛的复杂性。为了获得最佳结果，药物选择应个性化，以确保患者的特征与药物特性之间的最佳匹配。NSAIDs是治疗炎症性疼痛的重要处方选择，扑热息痛的最新结果质疑其在临床实践中的适当使用，提高了对临床实践指南中的建议进行重新评估的必要性。
增加临床医生对治疗不同疼痛机制的可用药理学选择的了解提供了潜在的安全，个性化治疗决策。我们希望它将通过提供最佳策略和新见解来帮助实现炎症性疼痛管理所需的变化，以实现管理疾病并为患者获得最佳利益的最终目标。
DompéFarmaceuticiSPA和PaoloProcacci基金会。
